PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies
PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.
PhoreMost, a United Kingdom-based biopharmaceutical company, and Oxford Biomedica, a gene and cell therapy group, have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor (CAR) T-cell therapies.
According to a Nov. 9, 2020 press release, the companies will use PhoreMost’s in-house expertise and next-generation phenotypic screening platform, SITESEEKER, to identify therapeutic candidates for Oxford Biomedica’s LentiVector gene therapy delivery system. Initially focusing on CAR-T therapies, the program aims to develop next generation cell therapies that provide improved efficacy and durability.
“This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER, offering an exciting opportunity to discover and accelerate the development of clinical stage products,” said Dr. Chris Torrance, CEO, PhoreMost, in the press release. “The natural complementarity between SITESEEKER and LentiVector offers great promise for this and future collaborations between the two companies.”
John Dawson, CEO of Oxford Biomedica, added in the press release, “We are excited to apply this next-generation technology to our LentiVector platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”
Financial details of the agreement were not disclosed.
Source: PhoreMost
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
